Suraksha Diagnostic, a well-known diagnostic chain in Eastern India, is all set to open its Initial Public Offering (IPO) for subscription on November 29, 2024. The company, which provides a wide range of pathology, radiology, and medical consultation services, aims to raise funds to expand its operations and enhance its service offerings. Here’s a quick guide to everything you need to know about the Suraksha Diagnostic IPO.
IPO Details
The Suraksha Diagnostic IPO is scheduled to open for subscription on Friday, November 29, 2024, and will close on Tuesday, December 3, 2024. The IPO price range has been fixed between ₹420 and ₹441 per share, with each share having a face value of ₹2. The minimum lot size for the IPO is 34 shares.
The allocation for anchor investors will take place on Thursday, November 28, 2024. These are institutional investors who may help set the tone for the IPO, often indicating the potential demand for the company’s shares.
For the public issue, the allocation of shares will be divided as follows:
- 50% of the shares will be reserved for Qualified Institutional Buyers (QIBs).
- 15% of the shares will be allocated to Non-Institutional Investors (NIIs).
- 35% of the shares will be reserved for retail investors. This gives regular investors a significant portion of the issue, making it accessible for small investors looking to take part in the IPO.
Listing Details and Allotment Process
The allotment process for the IPO is scheduled to be finalized on Wednesday, December 4, 2024. Refunds for unsuccessful applicants are likely to be processed starting Thursday, December 5, 2024, and shares will be credited to the allottees’ demat accounts on the same day. The listing of shares is expected to take place on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on Friday, December 6, 2024.
As of November 28, 2024, the Grey Market Premium (GMP) for the Suraksha Diagnostic IPO is ₹0, indicating that the shares are being traded at their issue price in the unofficial grey market. This suggests that investors are not expecting a significant premium above the issue price at the time of listing.
Before deciding whether to invest in the Suraksha Diagnostic IPO, it’s essential to consider the company’s strong financial track record, its expansive network, and the overall growth prospects in the Indian healthcare sector. The company’s use of advanced technology and its reputable management team further add to its appeal. However, like all investments, it is important to do thorough research and consult with a financial advisor to make an informed decision.
Overall, Suraksha Diagnostic’s IPO presents an exciting opportunity for retail investors looking to tap into the growing healthcare market in India. With a solid track record and future growth potential, the company could be well-positioned to generate value for its shareholders.
